The FDA Guidance on therapeutic cancer vaccines: The need for revision to include preventive cancer vaccines or for anewguidance dedicated to them

Olivera J. Finn, Samir N. Khleif, Ronald B. Herberman

Research output: Contribution to journalArticle

3 Scopus citations


Cancer vaccines based on antigens derived from self molecules rather than pathogens have been under basic and clinical investigations for many years. Up until very recently, they had been tested primarily in the setting of metastatic disease with the goal to engage the immune system in slowing down disease progression. Many therapeutic vaccine trials, either investigator initiated or led by pharmaceutical companies, have been completed and many are currently ongoing, following the FDA Guidance on therapeutic cancer vaccines published in 2011. In recent years, the target of cancer vaccines is being shifted to early cancer and even premalignant disease with the goal of preventing cancer. Although some issues addressed in the FDA Guidance on therapeutic vaccines apply to preventive vaccines, many do not. Here, we discuss a set of recommendations for revising the current Guidance to also cover preventive vaccines, or to include in a new Guidance dedicated specifically to vaccines for cancer prevention.

Original languageEnglish (US)
Pages (from-to)1011-1016
Number of pages6
JournalCancer Prevention Research
Issue number11
StatePublished - Nov 2015


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this